Opendata, web and dolomites

TARGETMENISCUS SIGNED

Targeting Meniscus Degradation in Osteoarthritis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 TARGETMENISCUS project word cloud

Explore the words cloud of the TARGETMENISCUS project. It provides you a very rough idea of what is the project "TARGETMENISCUS" about.

chemist    tears    operatively    donor    hard    mass    tissue    osteoarthritis    resonance    oa    consisting    imaging    wp2    urgent    stage    collaborations    revealed    my    knees    degeneration    prior    biomarkers    degenerative    7t    follow    caused    proteomics    population    modifying    undergo    tesla    synovial    orthopaedic    track    disease    packages    compositional    ultra    meniscal    team    analytical    molecular    expertise    spectrometry    linked    combined    healthy    ups    dedication    replacements    menisci    biobank    exploratory    burden    stimulating    entity    treatment    resolution    mri    intervention    frequent    proteome    knee    arthroscopy    patients    continued    pharmaceutical    wp1    total    international    arthroscopies    biostatistician    sequences    discover    trauma    leads    principal    investigator    materials    cartilage    members    ageing    link    joint    fluid    medical    surgery    physicist    internationally    surgeons    quality    regeneration    meniscus    proof    matrix    record    preventing    first    hyaline    magnetic    goals    degradation    identification    blood    human   

Project "TARGETMENISCUS" data sheet

The following table provides information about the project.

Coordinator
LUNDS UNIVERSITET 

Organization address
address: Paradisgatan 5c
city: LUND
postcode: 22100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Total cost 1˙973˙764 €
 EC max contribution 1˙973˙764 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2017-COG
 Funding Scheme ERC-COG
 Starting year 2018
 Duration (year-month-day) from 2018-08-01   to  2023-07-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    LUNDS UNIVERSITET SE (LUND) coordinator 1˙973˙764.00

Map

 Project objective

My goal is to determine the molecular degradation of meniscus tissue, a “new” disease that leads to degenerative meniscus tears and osteoarthritis (OA). My prior research has revealed that meniscus tears are a frequent entity in OA, not typically caused by knee trauma. By focusing on the meniscus, we aim to discover novel biomarkers and new targets for pharmaceutical intervention against OA, by preventing meniscus degradation and stimulating its regeneration. In our ageing population, the burden of OA is rapidly increasing, making the first disease-modifying OA treatment an urgent matter.

The proposal is based on my biobank consisting of human tissue from total knee joint replacements, knee arthroscopies, and healthy donor knees, including menisci, synovial fluid, hyaline cartilage, and blood. The two linked work packages are:

WP1 Proteomics: Identification of the proteome of the meniscal matrix and biomarkers of degeneration using exploratory and targeted mass spectrometry. WP2 7T imaging: Arthroscopy patients will undergo ultra-high field 7-Tesla magnetic resonance imaging (MRI) pre-operatively and at two follow-ups. Using both high-resolution and emerging compositional imaging sequences, we will determine meniscus matrix degradation and hyaline cartilage quality changes after knee surgery. Importantly, we will link proteomics with early stage knee OA development to provide proof-of-concept that the identified biomarkers and molecular treatment targets are associated with OA.

My key team members include orthopaedic surgeons, an analytical chemist with expertise in mass spectrometry, a medical physicist with expertise in MRI, and a biostatistician. We further work in international collaborations. As the principal investigator, I have an internationally recognized track record in OA research, with a novel focus on the meniscus. We will accomplish our goals by our combined expertise, unique materials, state-of-the-art methods, dedication, and continued hard work.

 Publications

year authors and title journal last update
List of publications.
2019 I. Kestilä, E. Folkesson, M.A. Finnilä, A. Turkiewicz, P. Önnerfjord, V. Hughes, J. Tjörnstrand, M. Englund, S. Saarakkala
Three-dimensional microstructure of human meniscus posterior horn in health and osteoarthritis
published pages: 1790-1799, ISSN: 1063-4584, DOI: 10.1016/j.joca.2019.07.003
Osteoarthritis and Cartilage 27/12 2020-04-03
2020 Elin Folkesson, Aleksandra Turkiewicz, Martin Rydén, Harini Velocity Hughes, Neserin Ali, Jon Tjörnstrand, Patrik Önnerfjord, Martin Englund
Proteomic characterization of the normal human medial meniscus body using data‐independent acquisition mass spectrometry
published pages: , ISSN: 0736-0266, DOI: 10.1002/jor.24602
Journal of Orthopaedic Research 2020-04-03

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "TARGETMENISCUS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "TARGETMENISCUS" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

DISINTEGRATION (2019)

The Mass Politics of Disintegration

Read More  

PROGRESS (2019)

The Enemy of the Good: Towards a Theory of Moral Progress

Read More  

iNANOVAC4CANCER (2019)

BIOHYBRID AND BIODEGRADABLE NANOVACCINES FOR CANCER IMMUNOTHERAPY

Read More